

Publikationsverzeichnis PD Dr med. univ. Thomas Winder, PhD (peer reviewed)

Originalarbeiten:

1. Posch F, Silina K, Leibl S, Mündlein A, Moch H, Siebenhüner A, Samaras P, Riedl J, Stotz M, Szkandera J, Stöger H, Pichler M, Stupp R, van den Broek M, Schraml P, Gerger A, Petrausch U, and **Winder T**. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. *Oncoimmunology* in press
2. Sauter M, Vavricka SR, Keilholz G, Heinrich H, **Winder T**, Kranzbühler H, Lombriser N, Misselwitz B. Surveillance of anal carcinoma after radiochemotherapy : A retrospective analysis of 80 patients. *Strahlenther Onkol.* 2017 Aug;193(8):639-647. doi: 10.1007/s00066-017-1159-0. Epub 2017 Jun 26.
3. Riedl JM, Posch F, Bezan A, Szkandera J, Smolle MA, **Winder T**, Rossmann CH, Schaberl-Moser R, Pichler M, Stotz M, Stöger H, Gerger A. Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study. *BMC Cancer.* 2017 Jun 15;17(1):415.
4. Bezan A, Posch F, Ploner F, Bauernhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Gary T, Samonigg H, Beyer J, **Winder T**, Hermanns T, Fankhauser CD, Gerger A, Stotz M. Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. *PLoS One.* 2017 Apr 21;12(4):e0176283.
5. Piegeler T, **Winder T**, Kern S, Pestalozzi B, Schneider PM, Beck-Schimmer B. Detection of circulating tumor cells in patients with esophagogastric or pancreatic adenocarcinoma using the CellSearch® system: An observational feasibility study. *Oncol Lett.* 2016 Aug;12(2):1513-1518. Impact Factor 1.48 (2015 Journal Citation Reports).
6. Bohanes P, Rankin C, Blanke CD, **Winder T**, Ulrich CM, Smalley SR, Rich TA, Martenson JA, Benson AB 3rd, Mayer RJ, Cripps CM, Danenberg KD, Makar KW, Zhang W, Benedetti JK, Lenz HJ. Pharmacogenetic analysis of INT 0144 trial: association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation. *Clin Cancer Res.* 2015 Apr 1;21(7):1583-90. Impact Factor 7.837 (2012 Journal Citation Reports)
7. Purohit B, **Winder T**, Maggio EM, Kollias SS. Aggressive primary olfactory neuroblastoma of the sphenoclivar region: A case report and literature review. *Laryngoscope.* 2015 Apr;125(4):822-5.
8. Muendlein A, Hubalek M, Geller-Rhomberg S, Gasser K, **Winder T**, Drexel H, Decker T, Mueller-Holzner E, Chamson M, Marth C, Lang AH. Significant

survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients. *Eur J Cancer*. 2014 Jun 5. pii: S0959-8049(14)00657-1. doi: 10.1016/j.ejca.2014.05.007. [Epub ahead of print]. Impact Factor 5.061 (2012 Journal Citation Reports).

9. Szkandera J, Pichler M, Absenger G, Stotz M, Weissmueller M, Samonigg H, Asslaber M, Lax S, Leitner G, **Winder T**, Renner W, Gerger A. A functional germline variant in GLI1 implicates Hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients. *Clin Cancer Res*. 2014 Mar 15;20(6):1687-97. Impact Factor 7.837 (2012 Journal Citation Reports)
10. **Winder T**, Giamas G, Wilson PM, Zhang W, Yang D, Bohanes P, Ning Y, Gerger A, Stebbing J, Lenz HJ. Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. *Pharmacogenomics J*. 2014 Feb;14(1):28-34. Impact Factor 5.134 (2012 Journal Citation Reports)
11. Ning Y, Gerger A, Zhang W, Hanna DL, Yang D, **Winder T**, Wakatsuki T, Labonte MJ, Stintzing S, Volz N, Sunakawa Y, Stremitzer S, El-Khoueiry R, Lenz HJ. Platin polymorphisms predict gender and stage-specific colon cancer recurrence after adjuvant chemotherapy. *Mol Cancer Ther*. 2014 Feb;13(2):528-39. Impact Factor 5.599 (2012 Journal Citation Reports)
12. Absenger G, Szkandera J, Stotz M, Pichler M, **Winder T**, Langsenlehner T, Langsenlehner U, Samonigg H, Renner W, Gerger A. A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer. *Mol Carcinog*. 2013 Nov;52 Suppl 1:96-102. doi: 10.1002/mc.22028. Epub 2013 Apr 26. Impact Factor 4.269 (2012 Journal Citation Reports)
13. Szkandera J*, **Winder T***, Stotz M, Weissmueller M, Langsenlehner T, Pichler M, Samonigg H, Renner W, Gerger A, Absenger G. A common gene variant in PLS3 predicts colon cancer recurrence in women. *Tumour Biol*. 2013 Aug;34(4):2183-8. Impact Factor 2.518 (2012 Journal Citation Reports)
14. Muendlein A, Lang AH, Geller-Rhomberg S, **Winder T**, Gasser K, Drexel H, Decker T, Mueller-Holzner E, Chamson M, Marth C, Hubalek M. Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer. *J Cancer Res Clin Oncol*. 2013 Mar;139(3):491-8. Impact Factor 2.914 (2012 Journal Citation Reports)
15. Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, **Winder T**, Hu-Lieskoven S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shriki J, Stebbing J, Lenz HJ. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. *Pharmacogenomics J*. 2013 Apr;13(2):173-80. Impact Factor 5.134 (2012 Journal Citation Reports)
16. **Winder T**, Wilson PM, Yang D, Zhang W, Ning Y, Power DG, Bohanes P, Gerger A, Tang LH, Shah M, Lenz HJ. An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence.

Pharmacogenomics J. 2013 Aug;13(4):342-8. Impact Factor 5.134 (2012 Journal Citation Reports)

17. Bohanes P, Yang D, Chhibar RS, Labonte MJ, **Winder T**, Ning Y, Gerger A, Benhaim L, Paez D, Wakatsuki T, Loupakis F, El-Khoueiry R, Zhang W, Lenz HJ. Influence of Sex on the Survival of Patients with Esophageal Cancer. J Clin Oncol. 2012 Jun 20;30(18):2265-72. Impact Factor 18.038 (2012 Journal Citation Reports)
18. Szkandera J, Absenger G, Stotz M, Weissmueller M, **Winder T**, Langsenlehner T, Samonigg H, Renner W, Schippinger W, Gerger A. The Functional Polymorphism of Erythropoietin Gene rs1617640 G>T Is Not Associated with Susceptibility and Clinical Outcome of Early-stage Breast Cancer. Anticancer Res. 2012 Aug;32(8):3473-8. Impact Factor 1.713 (2012 Journal Citation Reports)
19. Lang AH, Geller-Rhomberg S, **Winder T**, Stark N, Gasser K, Hartmann B, Kohler B, Grizelj I, Drexel H, Muendlein A. A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients. BMC Cancer. 2012 Jan 17;12(1):20. Impact Factor 3.333 (2012 Journal Citation Reports)
20. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, **Winder T**, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011 Nov 1;17(21):6934-43. Impact Factor 7.837 (2012 Journal Citation Reports)
21. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, **Winder T**, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ. Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2011 Sep 1;17(17):5783-92. Impact Factor 7.837 (2012 Journal Citation Reports)
22. Grimminger PP, Shi M, Barrett C, Lebwohl D, Danenberg KD, Brabender J, Vigen CL, Danenberg PV, **Winder T**, Lenz HJ. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials. Pharmacogenomics J. 2012 Oct;12(5):404-11. Impact Factor 5.134 (2012 Journal Citation Reports)
23. **Winder T**, Bohanes P, Zhang W, Yang D, Power DG, Ning Y, Gerger A, Wilson PM, Tang LH, Shah M, Lee AS, and Lenz HJ. GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric- and colorectal cancer patients. Ann Oncol. 2011 Nov;22(11):2431-9. Impact Factor 7.384 (2012 Journal Citation Reports)
24. **Winder T**, Ning Y, Yang D, Zhang W, G Power DG, Bohanes P, Gerger A, Wilson PM, Lurje G, Tang LH, Shah M and Lenz HJ. Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma (GA). Int J Cancer 2011 Sep 1;129(5):1096-104. Impact Factor 6.198 (2012 Journal Citation Reports) #∞

25. **Winder T**, Zhang W, Yang D, Ning Y, Bohanes P, Gerger A, Wilson P, Pohl A, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. Germline polymorphisms in genes involved in the IGF1-pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. *Clin Cancer Res.* 2010 Nov 15;16(22):5591-602. Impact Factor 7.837 (2012 Journal Citation Reports)
26. Alois H. Lang, Heinz Drexel, Simone Geller-Rhomberg, Nicole Stark, **Thomas Winder**, Kathrin Geiger, and Axel Muendlein. Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF. *J Mol Diagn.* 2011 Jan;13(1):23-8. Impact Factor 3.952 (2012 Journal Citation Reports)
27. Muendlein A, Saely CH, Geller-Rhomberg S, Sonderegger G, Rein P, **Winder T**, Beer S, Vonbank A, Drexel H. Single Nucleotide Polymorphisms of TCF7L2 Are Linked to Diabetic Coronary Atherosclerosis. *PLoS One.* 2011 Mar 15;6(3):e17978. Impact Factor 3.730 (2012 Journal Citation Reports)
28. Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A, Ning Y, Bohanes P, Gerger A, **Winder T**, Hollywood E, Danenberg KD, Saltz L, Lenz HJ. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). *Anticancer Res.* 2010 Oct;30(10):4209-17. Impact Factor 1.713 (2012 Journal Citation Reports)
29. Wu Zhang*, **Thomas Winder***, Yan Ning, Alexandra Pohl, Dongyun Yang, Michael Kahn, Georg Lurje, Melissa J. LaBonte, Peter M. Wilson, Michael A Gordon, Siwen Hu, David J. Mauro, Christiane Langer, Eric K. Rowinsky and Heinz-Josef Lenz. A let-7 microRNA binding site polymorphism in 3'-untranslated region(UTR) of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. *Ann Oncol.* 2011 Jan;22(1):104-9. Impact Factor 7.384 (2012 Journal Citation Reports) *
30. Pohl A, Azuma M, Zhang W, Yang D, Ning Y, **Winder T**, Danenberg K, Lenz H-J. Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer. *Pharmacogenomics J.* 2011 Apr;11(2):93-9. Impact Factor 5.134 (2012 Journal Citation Reports)
31. Lurje G, Leers JM, Pohl A, Oezcelik A, Zhang W, Ayazi S, **Winder T**, Ning Y, Yang D, Klipfel NE, Chandrasoma P, Hagen JA, Demeester SR, Demeester TR, Lenz HJ. Genetic Variations in Angiogenesis Pathway Genes Predict Tumor Recurrence in Localized Adenocarcinoma of the Esophagus. *Ann Surg.* 2010 May;251(5):857-64. Impact Factor 6.329 (2012 Journal Citation Reports)
32. **Winder T***, Mundlein A*, Rhomberg S, Dirschmid K, Hartmann B, Knauer M, Drexel H, Wenzl E, De Vries A, Lang A. Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. *Oncol Rep.* 2009 May;21(5):1283-7. Impact Factor 2.297 (2012 Journal Citation Reports)

33. Muendlein A, Geller-Rhomberg S, Saely CH, **Winder T**, Sonderegger G, Rein P, Beer S, Vonbank A, Drexel H. Significant impact of chromosomal locus 1p13.3 on serum LDL cholesterol and on angiographically characterized coronary atherosclerosis. *Atherosclerosis* 2009; 206:494-9. Impact Factor 3.706 (2012 Journal Citation Reports)
34. Muendlein A, Saely CH., Rhomberg S., Sonderegger G., Loacker S., Rein P, Beer S, Vonbank A, **Winder T**, Drexel H. Evaluation of the association of genetic variants on the chromosomal loci 9p21.3, 6q25.1, and 2q36.3 with angiographically characterized coronary artery disease. *Atherosclerosis* 2009; 205:174-80. Impact Factor 3.706 (2012 Journal Citation Reports)
35. Knauer M, Haid A, Schneider Y, Köberle-Wührer R, Lang A, **Winder T**, Alton R, Jasarevic Z, Säly C, Offner FA, Wenzl E, deVries A. Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancer. *Eur J Surg Oncol.* 2009 Aug;35(8):798-804. Impact Factor 2.614 (2012 Journal Citation Reports)

Fallbeschreibungen:

1. **Winder T**, Schuster A, Becherer A, Gasser K, De Vries A, Gruber-Mösenbacher U, Mündlein A, Drexel H, Lang A. Advanced inoperable type B3 thymoma; Monitoring of a novel therapeutic approach with radio-chemotherapy. *Nuklearmedizin.* 2010;49(5):N20-1.
2. **Winder T**, Mündlein A, Gasser K, Lingg G, Walser J, Karner-Hanusch J, Dirschmid K, Drexel H, Lang A. Challenges and pitfalls in HNPCC: A Pedigree of an Austrian HNPCC Family Beyond four Generations! *Memo* 2009; 2:41-4
3. Schranz M, Talasz H, Graziadei I, **Winder T**, Sergi C, Bogner K, Vogel W, Zoller H. Diagnosis of hepatic iron overload: a family study illustrating pitfalls in diagnosing hemochromatosis. *Diagn Mol Pathol.* 2009 Mar;18(1):53-60.

Übersichtsarbeiten (Reviews):

1. Nadal C, **Winder T**, Gerger A, Tougeron D. Future perspectives of circulating tumor DNA in colorectal cancer. *Tumour Biol.* 2017 May;39(5):1010428317705749.
2. Siebenhüner A, **Winder T**, Petrowsky H, Clavien PA, Pestalozzi B. Therapy of metastatic colorectal carcinoma exemplified in metachronous liver metastases. *Praxis (Bern 1994).* 2015 Jan 14;104(2):67-79.
3. Hohla F, **Winder T**, Greil R, Rick FG, Block NL, Schally AV. Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. *World J Gastroenterol.* 2014 May 28;20(20):6102-6112.

4. **Winder T**, Lenz H-J. Mucinous Adenocarcinomas with Intra-Abdominal Dissemination: "A Review of Current Therapy." *Oncologist* 2010;15(8):836-44.
5. **Winder T**, Lenz H-J. Beyond KRAS: A new pathway approach in metastatic colorectal cancer patients. *Lancet Oncol.* 2010 Aug;11(8):706-7.
6. **Winder T**, Lenz H-J. Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer. *Gastroenterology.* 2010 Jun;138(6):2163-76.
7. **Winder T**, Lenz H-J. Molecular Predictive and Prognostic Markers in Colon Cancer. *Cancer Treat Rev.* 2010 Nov;36(7):550-6.
8. **Winder T**, Lenz H-J. Predicting response of metastatic colorectal cancer to therapy using biological markers. *American Journal of Hematology and Oncology* 2009 Nov;8(11);547-549
9. **Winder T**, Scheithauer W, Lang A. K-ras mutations and cetuximab in colorectal cancer. *N Engl J Med.* 2009 Feb 19;360(8):834-5
10. Bohanes P, Labonte MJ, **Winder T**, Lenz HJ. Predictive molecular classifiers in colorectal cancer. *Semin Oncol.* 2011 Aug;38(4):576-87.
11. Muendlein A, **Winder T**, Loacker S, Drexel H. Einfluss von DNA-Variationen auf die koronare Herzerkrankung. *Journal für Kardiologie* 2008: 11-12: 342-6.

Buchbeiträge:

1. **Winder T**, Lenz H-J. Molekulare Diagnostik und Response Prädiktion. Siewert, *Praxis der Viszeralchirurgie - Onkologische Chirurgie.* Springer Verlag 3. Auflage 2010;187-197. ISBN 978-3-642-03807-5
2. **Winder T**, Lenz H-J. Molecular Prognostic Markers in Colon Cancer. Chapter 6 in *Metastasis in colorectal cancer.* Springer 1st Edition, 2010, XVI, 416 p., Hardcover . ISBN: 978-90-481-8832-1

* Both authors contributed equally